Merck's dual orexin receptor antagonist suvorexant is approaching the regulatory finish line, 15 years after orexins were discovered.
Rights and permissions
About this article
Cite this article
Osborne, R. First-in-class insomnia drug on the brink of approval nod. Nat Rev Drug Discov 12, 492–493 (2013). https://doi.org/10.1038/nrd4067
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4067
- Springer Nature Limited